Cardiol Therapeutics Inc. reports clinical, financing, and corporate updates as a late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead oral small-molecule candidate, CardiolRx, modulates inflammasome pathway activation associated with inflammation and fibrosis in pericarditis, myocarditis, and heart failure.
Recurring developments include the MAVERIC program in recurrent pericarditis, the completed ARCHER Phase II study in acute myocarditis, peer-reviewed publication of clinical data, U.S. trial-network updates, intellectual-property disclosures, and development of CRD-38 for heart failure and other inflammatory heart diseases. Company news also covers bought deal financings, common share and warrant offerings, annual operating updates, and healthcare conference presentations.
Cardiol Therapeutics (CRDL) reached its original 110-patient enrollment target for the Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis ahead of its end-of-September 2026 guidance and will expand enrollment to up to 150 patients.
The Steering Committee recommended the expansion after a blinded review showed fewer recurrences than expected, which the company views as encouraging, and aims to preserve statistical power for assessing CardiolRx™'s ability to reduce recurrence risk. Topline results are now anticipated in mid-2027, compared with prior Q1 2027 guidance, and existing capital is expected to fund MAVERIC through completion with a cash runway into Q1 2028.
Cardiol Therapeutics (CRDL) has received proceeds of over USD $7 million from the exercise of outstanding common share purchase warrants, strengthening its balance sheet and extending its cash runway into H1 2028.
The funds are expected to support operations through topline data from the pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis and to help prepare a potential New Drug Application, subject to favorable trial results and regulatory input. Of 5,712,500 warrants originally issued in October 2025, 425,000 remained unexercised as of September 15, 2026, representing additional potential gross proceeds of USD $573,750. Cardiol has exercised its Acceleration Right, causing all remaining warrants to expire at 4:00 p.m. (Eastern Time) on October 16, 2026 if not exercised.
Cardiol Therapeutics (CRDL) filed a US$150 million preliminary short form base shelf prospectus in Canada and a corresponding Form F‑10 registration statement with the U.S. SEC under the multijurisdictional disclosure system. No securities are being offered with this filing, and the company is not obligated to conduct any offering.
Once the final shelf is receipted and the registration statement is effective, Cardiol may issue, over a 25‑month period, Class A common shares, debt securities, warrants, subscription receipts, units, or combinations thereof, up to an aggregate initial offering price of US$150 million or equivalent. At the request of Ontario Securities Commission staff, the shelf includes expanded tabular and narrative disclosure on research and development programs, allocation of R&D spending, disaggregated general and administrative expenses, and the intended versus actual use of proceeds from the October 2024 financing.
Cardiol Therapeutics (CRDL) will participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 14, 2026, at 10:30 a.m. EDT.
The event will take place at the Lotte New York Palace Hotel, in the Louis Room on the 4th floor, and a live webcast will be available under “Events & Presentations” in the Investors section of Cardiol’s website. Cardiol is a late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease, led by its small-molecule candidate CardiolRx™, which is being evaluated in the Phase III MAVERIC trial for recurrent pericarditis and has U.S. FDA Orphan Drug Designation for pericarditis.
Cardiol Therapeutics (NASDAQ: CRDL, TSX: CRDL) will participate in a Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference at the InterContinental Boston Hotel on August 11, 2026, at 9:00 a.m. EDT. A live webcast will be available via the Investors “Events & Presentations” section on the company’s website.
Cardiol is a late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease. Lead candidate CardiolRx™ is being evaluated in the Phase III MAVERIC trial for recurrent pericarditis and has Orphan Drug Designation from the U.S. FDA. The completed Phase II ARCHER study assessed CardiolRx™ in acute myocarditis. Cardiol is also developing CRD-38, a subcutaneous formulation targeting inflammatory heart disease, including heart failure.
Cardiol Therapeutics (NASDAQ: CRDL; TSX: CRDL) announced that results from its Phase II MAvERIC study of CardiolRx™ in recurrent pericarditis have been published in the peer-reviewed Journal of the American Heart Association. The study found CardiolRx™ was associated with rapid and sustained reductions in pericarditis pain and inflammation in patients with high baseline disease burden, substantial decreases in pericarditis episodes per year, and a favorable safety and tolerability profile.
According to Cardiol, these Phase II findings provided the clinical rationale for MAVERIC, a randomized, double-blind, placebo-controlled pivotal Phase III trial evaluating CardiolRx™ for reducing the risk of pericarditis recurrence. Enrollment in MAVERIC is now approaching completion, supported by strong patient interest and highlighting the unmet need in recurrent pericarditis.
Cardiol Therapeutics (NASDAQ: CRDL), a late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease, will join a fireside chat at the B. Riley Securities Mind, Muscle & Vision Summit in Boston on July 16, 2026 at 12:20 p.m. EDT.
The event takes place at the InterContinental Boston Hotel, Abigail Adams Salon B.
Cardiol Therapeutics (NASDAQ: CRDL, TSX: CRDL) reported voting results from its Annual General Meeting held virtually on June 24, 2026. Shareholders approved all management resolutions, including the election of eight directors and the appointment of BDO Canada LLP as auditor for the next fiscal year.
Cardiol Therapeutics (NASDAQ:CRDL) will webcast its virtual Annual General Meeting of Shareholders on June 24, 2026, at 4:30 p.m. EDT.
The AGM will be held as a live webcast only, with participation and voting details available on the company’s investor events webpage.
Cardiol Therapeutics (NASDAQ:CRDL) will participate in a Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ in New York.
The session is scheduled for May 19, 2026 at 1:30 p.m. EDT, with a live webcast and a replay available for 90 days.